Product news

Share this article:
The FDA has approved Sucampo Pharmaceuticals' supplemental NDA for Amitiza (lubiprostone) to treat irritable bowel syndrome with constipation in women 18 years of age or older. As a result of the approval, Sucampo Pharmaceuticals will receive a development milestone payment of $50 million from Takeda in accordance a prior licensing agreement. Sucampo Pharmaceuticals and Takeda will jointly market Amitiza in the US and Canada. 
 
The FDA approved Watson Pharmaceuticals' Mixject, a new delivery system for Trelstar (triptorelin pamoate for injectable suspension), a palliative treatment for advanced prostate cancer.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.